Great interest for COR-1167 presentation at ESC Heart Failure 2024 in Lisbon: the promising results of COR-1167 to treat worsening heart failure in a sheep model were very well received. Attendees were eager to find out the outcomes of the ongoing phase 1 trial.
Corteria Pharmaceuticals
Recherche en biotechnologie
Interceptive therapies for the treatment of heart failure subpopulations
À propos
Development of transformative therapies for the treatment of worsening and acute decompensated heart failure
- Site web
-
http://www.corteriapharma.com
Lien externe pour Corteria Pharmaceuticals
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 2-10 employés
- Siège social
- Paris
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2021
Lieux
-
Principal
Obtenir l’itinéraire
128 rue de La Boetie
75008 Paris, FR
Employés chez Corteria Pharmaceuticals
Nouvelles
-
Corteria team is very happy to announce a Series A financing of €65M that will help bring our 3 programs into clinic. Thanks to our new investors Orbimed and Jeito Capital for their trust in our science and team, and the existing investors (Kurma Partners, Fountain Healthcare, V-Bio Ventures, InVivo Capital, Omnes Capital) for their continuous support, and to McDermott throughout the process.
-
At ESC 2023, the acute effects of the new long-acting CRF2 selective agonist COR-1167 in a rat model of heart failure with reduced ejection fraction were presented for the first time ! COR-1167 rapidly improved cardiac function through its mild positive inotropic and marked lusitropic effects after a single subcutaneous injection demonstrating that CRF2 receptor agonists potentially offer new therapeutic options for the treatment of heart failure.